A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea.
10.3346/jkms.2017.32.5.810
- Author:
Yong Joo KIM
1
;
Peipei LI
;
Jong Myeon HONG
;
Keun Ho RYU
;
Eunwoo NAM
;
Mi Soo CHANG
Author Information
1. Department of Pediatrics, College of Medicine, Hanyang University, Seoul, Korea. kyjoo@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatitis B antibody;
South Korea;
Booster;
Plasma-derived Vaccine;
Recombinant DNA Vaccine;
Children
- MeSH:
Adolescent;
Child;
Hepatitis B Surface Antigens;
Hepatitis B virus;
Hepatitis B*;
Hepatitis*;
Humans;
Korea*;
Retrospective Studies;
Seroconversion;
Serologic Tests;
Vaccination*;
Vaccines;
Vaccines, Synthetic
- From:Journal of Korean Medical Science
2017;32(5):810-816
- CountryRepublic of Korea
- Language:English
-
Abstract:
The antibody to hepatitis B surface antigen (anti-HBs) seropositivity rate after 3 doses of hepatitis B virus (HBV) vaccination during infancy period is known to be higher than 90%. However, a considerable number of vaccines do not form protective anti-HBs or chronologic decrease of anti-HBs. We retrospectively collected data of HBV serologic test results in 20,738 individuals from 2000 to 2015. After exclusion criteria were applied, 19,072 individuals were included. We analyzed the anti-HBs seropositivity rate, anti-HBs disappearance rate, anti-HBs positive seroconversion rate after receiving a booster vaccine, and the difference in anti-HBs positivity between the 2 groups; group A (born before 2005, while both recombinant vaccines and plasma-derived vaccines were used) and group B (born after 2005, when only recombinant vaccines were used by national regulation). The anti-HBs seropositivity rate was 55.8%, but there was a significant difference in the rate of seropositivity for anti-HBs between the group A and B (53.0% vs. 78.1%, P < 0.001). There was no significant age-adjusted difference in the mean seropositivity rate between the 2 groups (P = 0.058). In addition, the anti-HBs positivity rate was significantly lower in the group A as compared with the group B during infancy (83.1% vs. 92.1%, P < 0.001). A total of 1,106 anti-HBs-positive subjects underwent serologic tests more than twice. Of these, 217 subjects (19.6%) showed anti-HBs disappearance. After booster vaccinations, 87.4% (83/95) achieved seroconversion from seronegative to seropositive. Our results highlight the importance of lifelong protection against HBV and the possible necessity of booster vaccination after adolescent period.
